IPR decision (February 7, 2018):
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent No.
|
Status
|
|
IPR2016-01370
|
July 20, 2016
|
Feb 8, 2017
|
Koios
Pharmaceuticals LLC
|
US 8,664,231
|
Final Written
Decision
(claims 1–22 are
patentable)
|
On US’231 patent, Antares & Frontier Therapeutic
previously filed IPRs (IPR2014-01091 & IPR2016-00649) which were terminated
by PTAB.
US 8,664,231 (Medac;
06/01/2029) – OB listed
1. A method for the treatment of
inflammatory autoimmune diseases in a patient in need thereof, comprising
subcutaneously administering to said patient a medicament comprising
methotrexate in a pharmaceutically acceptable solvent at a concentration of
more than 30 mg/ml.
No comments:
Post a Comment